Recruiting
A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population
A Translational Study to Describe Asthma Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes associated with Differential Outcomes that may Support Future Development of Personalised Treatment Strategies in Chinese Population
ClinicalTrials.gov IDNCT06419413
PhaseNot Applicable
Enrollment355
SponsorAstraZeneca
Age18 Years
SexALL
Conditions studied
Asthma
About this study
A Translational Study to Describe Asthma Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes associated with Differential Outcomes that may Support Future Development of Personalised Treatment Strategies in Chinese Population
Primary outcomes
- Descriptive summary of demographic and subject characteristic, clinical characteristics and functional deliverables. (At baseline)
- Descriptive summary of biomarker level. (At baseline)
- Statistical clustering of key biomarkers. (At baseline)
- FEV1 level (At baseline)
- Forced Vital Capacity (FVC) (At baseline)
- Maximal Mid Expiratory Flow (MMEF) (At baseline)
- Airway remodeling (At baseline)
- Gas trapping (At baseline)
Eligibility information
Inclusion Criteria:
* Age 18 to 75 years of age
* acceptable FEV1 (according to ATS and ERS)
* compliance with study procedures All Asthma Cohorts
* physician diagnosed Asthma greater or equal to 3 months prior to screening visit
Exclusion Criteria:
* history of alcohol or drug abuse within the past year
* pregnant at time of an assessment
* has an altered mental status at the time of informed consent
* receipt marketed or investigational biologic(s) within 3 months or 5 half-lives prior to visit 1, whichever is longer
* history or current upper or lower respiratory infection or symptoms within 2 weeks of baseline assessments
* terminal diseases and/or organ failure or participants otherwise considered not appropriate for the study participation
* Receipt LTRAs or 5-lipoxygenase (5-LO) inhibitors (eg zileuton and montelukast) within 1 month or 5 half-lives prior to baseline, whichever is longer.
Study locations
- Research Site, Chengdu, Sichuan China
- Research Site, Beijing, China
- Research Site, Changsha, China
- Research Site, Dongguan, China
- Research Site, Foshan, China
- Research Site, Guangzhou, China
- Research Site, Hainan, China
- Research Site, Hohhot, China
- Research Site, Huizhou, China
- Research Site, Kunming, China
Showing 10 of 21 reported sites. See the official listing for all locations.
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.